May 12th 2021
Columbia University Irving Medical Center will partner with Advaxis, Inc. to fund a phase 1 clinical trial that seeks to examine the novel off-the-shelf neoantigen immunotherapy agent ADXS-504 in patients with biochemically recurrent prostate cancer.
May 7th 2021
Erminia Massarelli, MD, MS, PhD, shares key updates in immunotherapy and targeted treatment for patients with NSCLC
May 6th 2021
The phase 3 IMpower133 trial, which examined atezolizumab plus platinum-based chemotherapy and etoposide in patients with untreated extensive-stage small cell lung cancer helped lay the foundation for the exploration of other novel immunotherapy combinations.
May 6th 2021
The FDA has granted priority review to applications that are seeking 2 approvals of pembrolizumab in combination with lenvatinib in advanced renal cell carcinoma and advanced endometrial carcinoma.
April 30th 2021
Arsen Osipov, MD, discusses the role of combination immunotherapy across multiple tumor types.
April 27th 2021
The FDA's Oncologic Drugs Advisory Committee voted 7 to 2 in support of maintaining the indication of atezolizumab in combination with nab-paclitaxel as a treatment for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors are PD-L1 positive.
April 26th 2021
The FDA’s Oncologic Drugs Advisory Committee is poised to move forward this week with a public review of 6 indications for immune checkpoint inhibitors granted under the agency’s accelerated approval process that later failed to reach thresholds for statistical significance for key end points in confirmatory clinical trials.
April 18th 2021
The frontline treatment landscape of renal cell carcinoma is exploding with immunotherapy-based options.
April 16th 2021
Jacob Sands, MD, discussed current approaches to the treatment of patients with early-stage and locally advanced non–small cell lung cancer.